Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 9Terminated 7Recruiting 7Unknown 3Not yet recruiting 3Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 198Nivolumab 146Carboplatin 133Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 112Paclitaxel 106Biopsy 97Cisplatin 94Radiotherapy 89durvalumab 83Dexamethasone 80atezolizumab 73Ipilimumab 66Gemcitabine 60Doxorubicin 60Rituximab 59Lenalidomide 56Docetaxel 55olaparib 51Etoposide 51Bevacizumab 51Fluorouracil 49Capecitabine 49Radiation 47Oxaliplatin 47Radiosurgery 43Prednisone 43venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Propranolol × Clear all
NCT06120140 2026-05-08

COCOON

Janssen Research & Development, LLC

Phase 2 Active not recruiting
305 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Emory University

Phase 2 Active not recruiting
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡